288 OCT1 AS A PROGNOSTIC FACTOR FOR PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Basic Research1 Apr 2011288 OCT1 AS A PROGNOSTIC FACTOR FOR PROSTATE CANCER Daisuke Obinata, Ken-ichi Takayama, Tomohiko Urano, Taro Murata, Jinpei Kumagai, Tetsuya Fujimura, Kazuhiro Ikeda, Kuniko Horie-Inoue, Satoru Takahashi, and Satoshi Inoue Daisuke ObinataDaisuke Obinata Tokyo, Japan More articles by this author , Ken-ichi TakayamaKen-ichi Takayama Tokyo, Japan More articles by this author , Tomohiko UranoTomohiko Urano Tokyo, Japan More articles by this author , Taro MurataTaro Murata Tokyo, Japan More articles by this author , Jinpei KumagaiJinpei Kumagai Tokyo, Japan More articles by this author , Tetsuya FujimuraTetsuya Fujimura Tokyo, Japan More articles by this author , Kazuhiro IkedaKazuhiro Ikeda Saitama, Japan More articles by this author , Kuniko Horie-InoueKuniko Horie-Inoue Saitama, Japan More articles by this author , Satoru TakahashiSatoru Takahashi Tokyo, Japan More articles by this author , and Satoshi InoueSatoshi Inoue Tokyo, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.380AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen receptor (AR) plays a role in prostate cancer development and progression. Alteration of AR coregulators expression leads to hypersensitivity of AR, which is supposed to be one of the mechanisms for prostate cancer progression to castrate -resistant state. Octamer transcription factor 1 (Oct1) is a ubiquitous member of the POU-homeodomain family that was found to be one of AR coregulators. Here, we examined the contribution of Oct1 in prostate cancer development. METHODS Immunocytochemical study for Oct1 and AR was performed in human prostate cancer cell line (LNCaP). Endogenous Oct1 was knocked down by siRNA targeting Oct1, and cell growth rate was measured using a MTS proliferation assay. Immunohistochemical study for Oct1 and AR expression was performed in 102 pathological prostate cancer specimens. Immunostained slides were evaluated for the proportion of positive cells to total cells (under 200x magnification) (score 0, none; score 1, <1/100; score 2, 1/100 to 1/10; score 3, 1/ 10 to 1/3; score 4, 1/3 to 2/3; score 5, >2/3) and the intensity (score 0, none; score 1, weak; score 2, moderate; score 3, strong) of positively stained cells. RESULTS By immunocytochemistry analysis, Oct1 was expressed in the nucleus in LNCaP cells. In addition, silencing of Oct1 expression with siRNA decreased LNCaP cell proliferation. Immunohistochemically analysis for Oct1 and AR in 102 prostate cancer specimens, the expression of Oct1 was positively correlated with high Gleason score (GS) and AR immunoreactivity (p = 0.0042, and p < 0.0001, respectively). Multivariate hazard analysis revealed significant correlations between strong Oct1 immunoreactivity and poor cancer-specific survival (p = 0.012, respectively). In addition, cancer-specific survival in strong expression of Oct1 cases was lower than in strong expression of AR expression cases. CONCLUSIONS Oct1 can be a prognostic factor in prostate cancer conjunctively with AR. These findings suggest that Oct1 may be a new therapeutic intervention in prostate cancer. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e117 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Daisuke Obinata Tokyo, Japan More articles by this author Ken-ichi Takayama Tokyo, Japan More articles by this author Tomohiko Urano Tokyo, Japan More articles by this author Taro Murata Tokyo, Japan More articles by this author Jinpei Kumagai Tokyo, Japan More articles by this author Tetsuya Fujimura Tokyo, Japan More articles by this author Kazuhiro Ikeda Saitama, Japan More articles by this author Kuniko Horie-Inoue Saitama, Japan More articles by this author Satoru Takahashi Tokyo, Japan More articles by this author Satoshi Inoue Tokyo, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...